Reactive oxygen species, vascular noxs, and hypertension: Focus on translational and clinical research

Antioxidants and Redox Signaling

Volumn 20, Issue 1, 2014, Pages 164-182

  Montezano, Augusto C ^a   Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ANGIOTENSIN II; CATALASE; GLUTATHIONE PEROXIDASE; ISOPROSTANE DERIVATIVE; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PEROXIREDOXIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; TYROSINE; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DOWN REGULATION; EXPERIMENTAL HYPERTENSION; EXTRACELLULAR MATRIX; GENETIC POLYMORPHISM; HYPERTENSION; HYPERTROPHY; INFLAMMATION; NITRATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE CELL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; BIOMEDICAL RESEARCH; BLOOD VESSELS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; NADPH OXIDASE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84880030138     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5302     Document Type: Review

References (239)

1. Adams V, Linke A, Krankel N, Erbs S, Gielen S, Mobius-Winkler S, Gummert JF, Mohr FW, Schuler G, and Hambrecht R. Impact of regular physical activity on the NAD(P)H oxidase and angiotensin receptor system in patients with coronary artery disease. Circulation 111: 555-562, 2005.
2. Adlam D, Bendall JK, De Bono JP, Alp NJ, Khoo J, Nicoli T, Yokoyama M, Kawashima S, and Channon KM. Relationships between nitric oxide-mediated endothelial function, eNOS coupling and blood pressure revealed by eNOS-GTP cyclohydrolase 1 double transgenic mice. Exp Physiol 92: 119-126, 2007.
3. Al Ghouleh I, Frazziano G, Rodriguez AI, Csa?nyi G, Maniar S, St Croix CM, Kelley EE, Egana LA, Song GJ, Bisello A, Lee YJ, and Pagano PJ. Aquaporin 1, Nox1, and Ask1 mediate oxidant-induced smooth muscle cell hypertrophy. Cardiovasc Res 97: 134-142, 2013.
4. Al Ghouleh I, Khoo NK, Knaus UG, Griendling KK, Touyz RM, Thannickal VJ, Barchowsky A, Nauseef WM, Kelley EE, Bauer PM, Darley-Usmar V, Shiva S, Cifuentes-Pagano E, Freeman BA, Gladwin MT, and Pagano PJ. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med 51: 1271-1288, 2011.
5. Al-Shebly MM and Mansour MA. Evaluation of oxidative stress and antioxidant status in diabetic and hypertensive women during labor. Oxid Med Cell Longev 2012: 329743-32976, 2012.
6. Al-Solaiman Y, Jesri A, Zhao Y, Morrow JD, and Egan BM. Low-sodium DASH reduces oxidative stress and improves vascular function in salt-sensitive humans. J Hum Hypertens 23: 826-830, 2009.
7. Altenhofer S, Kleikers PW, Radermacher KA, Scheurer P, Rob Hermans JJ, Schiffers P, Ho H, Wingler K, and Schmidt HH. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci 69: 2327-2343, 2012.
8. Amanso AM, Debbas V, and Laurindo FR. Proteasome inhibition represses unfolded protein response and Nox4, sensitizing vascular cells to endoplasmic reticulum stressinduced death. PLoS One 6: e14591, 2011.
9. Anilkumar N, Jose GS, Sawyer I, Santos CX, Sand C, Brewer AC, Warren D, and Shah AM. A 28-kDa splice variant of NADPH oxidase-4 is nuclear-localized and involved in redox signaling in vascular cells. Arterioscler Thromb Vasc Biol 33: e104-e112, 2013.
10. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, Antonopoulos AS, Demosthenous M, Marinou K, Hale A, Paschalis A, Psarros C, Triantafyllou C, Bendall J, Casadei B, Stefanadis C, and Channon KM. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 124: 335-345, 2011.
11. Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L, Molango S, Heitz F, Merlot C, Szyndralewiez C, Page P, and Brenner DA. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology 56: 2316-2327, 2012.
12. Babior BM. NADPH oxidase. Curr Opin Immunol 16: 42-47, 2004.
13. Ba?nfi B, Tirone F, Durussel I, Knisz J, Moskwa P, Molna?r GZ, Krause KH, and Cox JA. Mechanism of Ca2 + activation of the NADPH oxidase 5 (NOX5). J Biol Chem 279: 18583-18591, 2004.
14. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, and Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57: 469-476, 2011.
15. Basset O, Deffert C, Foti M, Bedard K, Jaquet V, Ogier-Denis E, and Krause KH. NADPH oxidase 1 deficiency alters caveolin phosphorylation and angiotensin II-receptor localization in vascular smooth muscle. Antioxid Redox Signal 11: 2371-2384, 2009.
16. Bedard K and Krause KH. The NOX family of ROSgenerating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313, 2007.
17. Bedard K, Jaquet V, and Krause KH. NOX5: from basic biology to signaling and disease. Free Radic Biol Med 52: 725-734, 2012.
18. BelAiba RS, Djordjevic T, Petry A, Diemer K, Bonello S, Banfi B, Hess J, Pogrebniak A, Bickel C, and Gorlach A. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med 42: 446-459, 2007.
19. Bir SC, Kolluru GK, Fang K, and Kevil CG. Redox balance dynamically regulates vascular growth and remodeling. Semin Cell Dev Biol 23: 745-757, 2012.
20. Bo S, Gambino R, Gentile L, Pagano G, Rosato R, Saracco GM, Cassader M, Durazzo M, and Cavallo-Perin P. Highnormal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. J Hypertens 27: 102-108, 2009.
21. Brand S, Amann K, and Schupp N. Angiotensin II-induced hypertension dose-dependently leads to oxidative stress and DNA damage in mouse kidneys and hearts. J Hypertens 31: 333-344, 2013.
22. Brieger K, Schiavone S, Miller FJ, Jr., and Krause KH. Reactive oxygen species: from health to disease. Swiss Med Wkly 17: 142-147, 2012.
23. Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, Correa J, Gagnon AM, Celso E. Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, amd Touyz RM. Adipocytes produce aldosterone through calcineurin/NFAT-dependent signaling pathway -Implications in diabetes-Associated obesity. Hypertension 59: 1069-1078, 2012.
24. Briones AM, Tabet F, Callera GE, Montezano AC, Yogi A, He Y, Quinn MT, Salaices M, and Touyz RM. Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. J Am Soc Hypertens 5: 137-153, 2011.
25. Bruno RM, Daghini E, Landini L, Versari D, Salvati A, Santini E, Di Paco I, Magagna A, Taddei S, Ghiadoni L, and Solini A. Dynamic evaluation of renal resistive index in normoalbuminuric patients with newly diagnosed hypertension or type 2 diabetes. Diabetologia 54: 2430-2439, 2011.
26. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, and Touyz RM. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/ NADPH oxidase/Rho kinase pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol 31: 1898-1907, 2011.
27. Byrne JA, Grieve DJ, Bendall JK, Li JM, Gove C, Lambeth JD, Cave AC, and Shah AM. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93: 802-805, 2003.
28. Caner M, Karter Y, Uzun H, Curgunlu A, Vehid S, Balci H, Yucel R, Guner I, Kutlu A, Yaldiran A, and Ozturk E. Oxidative stress in human sustained and white coat hypertension. Int J Clin Pract 60: 1565-1571, 2006.
29. Capone C, Faraco G, Peterson JR, Coleman C, Anrather J, Milner TA, Pickel VM, Davisson RL, and Iadecola C. Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. J Neurosci 32: 4878-4886, 2012.
30. Chang SY, Chen YW, Zhao XP, Chenier I, Tran S, SauveA, Ingelfinger JR, and Zhang SL. Catalase prevents maternal diabetes-induced perinatal programming via the Nrf2-HO-1 defense system. Diabetes 61: 2565-2574, 2012.
31. Chapple SJ, Siow RC, and Mann GE. Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int J Biochem Cell Biol 44: 1315-1320, 2012.
32. Chen DD, Dong YG, Yuan H, and Chen AF. Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension. Hypertension 59: 1037-1043, 2012.
33. Chen F, Yu Y, Qian J, Wang Y, Cheng B, Dimitropoulou C, Patel V, Chadli A, Rudic RD, Stepp DW, Catravas JD, and Fulton DJ. Opposing actions of heat shock protein 90 and 70 regulate nicotinamide adenine dinucleotide phosphate oxidase stability and reactive oxygen species production. Arterioscler Thromb Vasc Biol 32: 2989-2999, 2012.
34. Chen H, Song YS, and Chan PH. Inhibition of NADPH oxidase is neuroprotective after ischemia-reperfusion. J Cereb Blood Flow Metab 29: 1262-1272, 2009.
35. Chen K, Kirber MT, Xiao H, Yang Y, and Keaney JF, Jr. Regulation of ROS signal transduction by NAD(P)H oxidase 4 localization. J Cell Biol 181: 1129-1139, 2008.
36. Chen K, Xie F, Liu S, Li G, Chen Y, Shi W, Hu H, Liu L, and Yin D. Plasma reactive carbonyl species: potential risk factor for hypertension. Free Radic Res 45: 568-574, 2011.
37. Chen X, Touyz RM, Park JB, and Schiffrin EL. Antioxidant effects of vitamins C and E are associated with altered activation of vascular NADPH oxidase and superoxide dismutase in stroke-prone SHR. Hypertension 38(3 Pt 2): 606-611, 2001.
38. Chrissobolis S, Banfi B, Sobey CG, and Faraci FM. Role of Nox isoforms in angiotensin II-induced oxidative stress and endothelial dysfunction in brain. J Appl Physiol 113: 184-191, 2012.
39. Cifuentes-Pagano E, Csanyi G, and Pagano PJ. NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS. Cell Mol Life Sci 69: 2315-2325, 2012.
40. Cioffi DL. Redox regulation of endothelial canonical transient receptor potential channels. Antioxid Redox Signal 15: 1567-1582, 2011.
41. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med 17: 1402-1409, 2010.
42. Collins AR, Lyon CJ, Xia X, Liu JZ, Tangirala RK, Yin F, Boyadjian R, Bikineyeva A, Pratico D, Harrison DG, and Hsueh WA. Age-Accelerated atherosclerosis correlates with failure to upregulate antioxidant genes. Circ Res 104: e42-e54, 2009.
43. Cook MD, Heffernan KS, Ranadive S, Woods JA, and Fernhall B. Effect of resistance training on biomarkers of vascular function and oxidative stress in young African-American and Caucasian men. J Hum Hypertens 2012 [Epub ahead of print]; DOI: 10.1038/jhh.2012.48.
44. Copple IM. The Keap1-Nrf2 cell defense pathway-A promising therapeutic target? Adv Pharmacol 63: 43-79, 2012.
45. Cottone S, Mule G, Guarneri M, Palermo A, Lorito MC, Riccobene R, Arsena R, Vaccaro F, Vadala A, Nardi E, Cusimano P, and Cerasola G. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant 24: 497-503, 2009.
46. Csa?nyi G, Yao M, Rodrguez AI, Ghouleh IA, Sharifi-Sanjani M, Frazziano G, Huang X, Kelley EE, Isenberg JS, and Pagano PJ. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol 32: 2966-2973, 2012.
47. Cunnington C, Van Assche T, Shirodaria C, Kylintireas I, Lindsay AC, Lee JM, Antoniades C, Margaritis M, Lee R, Cerrato R, Crabtree MJ, Francis JM, Sayeed R, Ratnatunga C, Pillai R, Choudhury RP, Neubauer S, and Channon KM. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 125: 1356-1366, 2012.
48. Di Castro S, Scarpino S, Marchitti S, Bianchi F, Stanzione R, Cotugno M, Sironi L, Gelosa P, Duranti E, Ruco L, Volpe M, and Rubattu S. Differential modulation of uncoupling protein 2 in kidneys of stroke-prone spontaneously hypertensive rats under high-salt/low-potassium diet. Hypertension 61: 534-541, 2013.
49. Dikalova A, Clempus R, Lassegue B, Cheng G, McCoy J, and Dikalov S, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation 112: 2668-2676, 2005.
50. Dikalova AE, Go?ngora MC, Harrison DG, Lambeth JD, Dikalov S, and Griendling KK. Upregulation of Nox1 in vascular smooth muscle leads to impaired endotheliumdependent relaxation via eNOS uncoupling. Am J Physiol Heart Circ Physiol 299: H673-H679, 2010.
51. Douglas G, Bendall JK, Crabtree MJ, Tatham AL, Carter EE, Hale AB, and Channon KM. Endothelial-specific Nox2 overexpression increases vascular superoxide and macrophage recruitment in ApoE?/? mice. Cardiovasc Res 94: 20-29, 2012.
52. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
53. Drummond GR, Selemidis S, Griendling KK, and Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453-471, 2011.
54. Dutta S and Rittinger K. Regulation of NOXO1 activity through reversible interactions with p22 and NOXA1. PLoS One 5: e10478, 2010.
55. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health. EFSA J 9: 2474-2478, 2011.
56. El Jamali A, Valente AJ, Lechleiter JD, Gamez MJ, Pearson DW, Nauseef WM, and Clark RA. Novel redox-dependent regulation of NOX5 by the tyrosine kinase c-Abl. Free Radic Biol Med 44: 868-881, 2008.
57. Feairheller DL, Park JY, Sturgeon KM, Williamson ST, Diaz KM, Veerabhadrappa P, and Brown MD. Racial differences in oxidative stress and inflammation: in vitro and in vivo. Clin Transl Sci 4: 32-37, 2011.
58. Fernandes DC, Manoel AHO, Wosniak J, and Laurindo FR. Protein disulfide isomerise overexpression in vascular smooth muscle cells induces spontaneous preemptive NAD(P)H oxidase activation and Nox1 mRNA expression: effects of nitrosothiol exposure. Arch Biochem Biophys 484: 197-204, 2009.
59. Fortuno A, Bidegain J, Robador PA, Hermida J, Lo?pez-Sagaseta J, Beloqui O, Dez J, and Zalba G. Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertension. Hypertension 54: 744-750, 2009.
60. Freel EM, Mark PB, Weir RA, McQuarrie EP, Allan K, Dargie HJ, McClure JD, Jardine AG, Davies E, and Connell JM. Demonstration of blood pressure-independent noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance imaging study. Circ Cardiovasc Imaging 5: 740-747, 2012.
61. Fukai T, Ishizaka N, Rajagopalan S, Laursen JB, Capers QT, and Taylor WR, et al. p22phox mRNA expression and NAD(P)H oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997.
62. Fulton DJ. Nox5 and the regulation of cellular function. Antioxid Redox Signal 11: 2443-2452, 2009.
63. Gavazzi G, Banfi B, Deffert C, Fiette L, Schappi M, Herrmann F, and Krause KH. Decreased blood pressure in NOX1-deficient mice. FEBS Lett 580: 497-504, 2006.
64. Geiszt M, Kopp JB, Va?rnai P, and Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 97: 8010-8014, 2000.
65. Geiszt M. NAD(P)H oxidases: new kids on the block. Cardiovasc Res 71: 289-299, 2006.
66. Giustarini D, Dalle-Donne I, Tsikas D, and Rossi R. Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 46: 241-281, 2009.
67. Glassman SJ. Vitiligo, reactive oxygen species and T-cells. Clin Sci 120: 99-120, 2011.
68. Godin N, Liu F, Lau GJ, Brezniceanu ML, Che?nier I, Filep JG, Ingelfinger JR, Zhang SL, and Chan JS. Catalase overexpression prevents hypertension and tubular apoptosis in angiotensinogen transgenic mice. Kidney Int 77: 1086-1097, 2010.
69. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, Dikalov S, Fukai T, and Harrison DG. Role of extracellular superoxide dismutase in hypertension. Hypertension 48: 473-481, 2006.
70. Greig D, Alcaino H, Castro PF, Garcia L, Verdejo HE, Navarro M, Lo?pez R, Mellado R, Tapia F, Gabrielli LA, Nogerol C, Chiong M, Godoy I, and Lavandero S. Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. J Heart Lung Transplant 30: 408-413, 2011.
71. Griendling KK, Sorescu D, Lassegue B, and Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20: 2175-2183, 2000.
72. Guerrero F, Thioub S, Goanvec C, Theunissen S, Feray A, Balestra C, and Mansourati J. Effect of tetrahydrobiopterin and exercise training on endothelium-dependent vasorelaxation in SHR. J Physiol Biochem 69: 277-287, 2013.
73. Guimaraes DD, Carvalho CC, and Braga VA. Scavenging of NADPH oxidase-derived superoxide anions improves depressed baroreflex sensitivity in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 39: 373-378, 2012.
74. Gupte SA, Kaminski PM, George S, Kouznestova L, Olson SC, Mathew R, Hintze TH, and Wolin MS. Peroxide generation by p47phox-Src activation of Nox2 has a key role in protein kinase C-induced arterial smooth muscle contraction. Am J Physiol Heart Circ Physiol 296: H1048-H1057, 2009.
75. Guzik TJ, Chen W, Gongora MC, Guzik B, Lob HE, Mangalat D, Hoch N, Dikalov S, Rudzinski P, Kapelak B, Sadowski J, and Harrison DG. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol 52: 1803-1809, 2008.
76. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, and Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656-1662, 2002.
77. Guzik TJ, Sadowski J, Guzik B, Jopek A, Kapelak B, Przybylowski P, Wierzbicki K, Korbut R, Harrison DG, and Channon KM. Coronary artery superoxide production and nox isoform expression in human coronary artery disease. Arterioscler Thromb Vasc Biol 26: 333-339, 2006.
78. Guzik TJ, Sadowski J, Kapelak B, Jopek A, Rudzinski P, Pillai R, Korbut R, and Channon KM. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 24: 1614-1620, 2004.
79. Hahn NE, Meischl C, Kawahara T, Musters RJ, Verhoef VM, van der Velden J, Vonk AB, Paulus WJ, van Rossum AC, Niessen HW, and Krijnen PA. NOX5 expression is increased in intramyocardial blood vessels and cardiomyocytes after acute myocardial infarction in humans. Am J Pathol 180: 2222-2229, 2012.
80. Han CY, Umemoto T, Omer M, Den Hartigh LJ, Chiba T, LeBoeuf R, Buller CL, Sweet IR, Pennathur S, Abel ED, and Chait A. NADPH oxidase-derived reactive oxygen species increases expression of monocyte chemotactic factor genes in cultured adipocytes. J Biol Chem 287: 10379-10393, 2012.
81. Harris DM, Cohn HI, Pesant S, and Eckhart AD. GPCR signalling in hypertension: role of GRKs. Clin Sci (Lond) 115: 79-89, 2008.
82. Harrison DG, Vinh A, Lob H, and Madhur MS. Role of the adaptive immune system in hypertension. Curr Opin Pharmacol 10: 203-207, 2010.
83. Hasnain BA and Mooradian AD. Recent trials of antioxidant therapy: what should we be telling our patients? Cleve Clin J Med 71: 327-334, 2004.
84. Hilenski LL, Clempus RE, Quinn MT, Lambeth JD, and Griendling KK. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 677-683, 2004.
85. Houston MC. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis 4: 165-183, 2010. http://news-medical.net/news/20121103/Genkyotexannounces-positive-results- from-GKT137831-Phase-I-studieson-healthy-subjects.aspx 87.
86. Huang BS, Zheng H, Tan J, Patel KP, and Leenen FH. Regulation of hypothalamic renin-Angiotensin system and oxidative stress by aldosterone. Exp Physiol 96: 1028-1038, 2011.
87. Hummel SL, Seymour EM, Brook RD, Kolias TJ, Sheth SS, and Rosenblum HR, Wells JM, Weder AB. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension 60: 1200-1206, 2012.
88. Hybertson BM, Gao B, Bose SK, and McCord JM. Oxidative stress in health and disease: the therapeutic potential of Nrf2 activation. Mol Aspects Med 32: 234-246, 2011.
89. Ismail S, Sturrock A, Wu P, Cahill B, Norman K, Huecksteadt T, Sanders K, Kennedy T, and Hoidal J. NOX4 mediates hypoxia-induced proliferation of human pulmonary artery smooth muscle cells: the role of autocrine production of transforming growth factor-{beta}1 and insulin-like growth factor binding protein-3. Am J Physiol Lung Cell Mol Physiol 296: 489-499, 2009.
90. Jaquet V, Scapozza L, Clark RA, Krause KH, and Lambeth JD. Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal 11: 2535-2552, 2009.
91. Jay DB, Papaharalambus CA, Seidel-Rogol B, Dikalova AE, Lassegue B, and Griendling KK. Nox5 mediates PDGFinduced proliferation in human aortic smooth muscle cells. Free Radic Biol Med 45: 329-335, 2008.
92. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, and Brandes RP.gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109: 1795-1801, 2004.
93. Juraschek SP, Guallar E, Appel LJ, and Miller ER 3rd. Effects of vitamin C supplementation on blood pressure: a meta-Analysis of randomized controlled trials. Am J Clin Nutr 95: 1079-1088, 2012.
94. Kagota S, Tada Y, Kubota Y, Nejime N, Yamaguchi Y, Nakamura K, Kunitomo M, and Shinozuka K. Peroxynitrite is involved in the dysfunction of vasorelaxation in SHR/ NDmcr-cp rats, spontaneously hypertensive obese rats. J Cardiovasc Pharmacol 50: 677-685, 2007.
95. Kakihana T, Nagata K, and Sitia R. Peroxides and peroxidases in the endoplasmic reticulum: integrating redox homeostasis and oxidative folding. Antioxid Redox Signal 16: 763-771, 2012.
96. Kalpdev A, Saha SC, and Dhawan V. Vitamin C and E supplementation does not reduce the risk of superimposed PE in pregnancy. Hypertens Pregnancy 30: 447-456, 2011.
97. Kalwa H, Sartoretto JL, Sartoretto SM, and Michel T. Angiotensin-II and MARCKS: a hydrogen peroxide-And RAC1-dependent signaling pathway in vascular endothelium. J Biol Chem 287: 29147-29158, 2012.
98. Kamenisch Y and Berneburg M. Progeroid syndromes and UV-induced oxidative DNA damage. J Investig Dermatol Symp Proc 14: 8-14, 2009.
99. Kim CH. Association between the p22(phox) -930A/G polymorphism and blood pressure in normotensive subjects. Hypertens Res 33: 786-787, 2010.
100. Kim HJ and Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 298: F662-F671, 2010.
101. Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, and Thapa P. NADPH oxidase inhibitors: a patent review. Expert Opin Ther Pat 21: 1147-1158, 2011.
102. Kishi T and Hirooka Y. Oxidative stress in the brain causes hypertension via sympathoexcitation. Front Physiol 3: 335-340, 2012.
103. Kodama R, Kato M, Furuta S, Ueno S, Zhang Y, Matsuno K, Yabe-Nishimura C, Tanaka E, and Kamata T. ROS-generating oxidases Nox1 and Nox4 contribute to oncogenic Rasinduced premature senescence. Genes Cells 18: 32-41, 2013.
104. Kruger R, Schutte R, Huisman HW, Van Rooyen JM, Malan NT, Fourie CM, Louw R, van der Westhuizen FH, van Deventer CA, Malan L, and Schutte AE. Associations between reactive oxygen species, blood pressure and arterial stiffness in black South Africans: the SABPA study. J Hum Hypertens 26: 91-97, 2012.
105. Kuklinska AM, Mroczko B, Musia1 WJ, Sawicki R, Kozieradzka A, Usowicz-Szarynska M, Kaminski K, Knapp M, Szmitkowski M. Hypotensive effect of atorvastatin is not related to changes in inflammation and oxidative stress. Pharmacol Rep 62: 883-890, 2010.
106. Labios M, Martnez M, Gabriel F, Guiral V, Dasi F, Beltra?n B, and Munoz A. Superoxide dismutase and catalase antioxidant activity in leucocyte lysates from hypertensive patients: effects of eprosartan treatment. J Renin Angiotensin Aldosterone Syst 10: 24-30, 2009.
107. Lacy F, Kailasam MT, O?Connor DT, Schmid-Schonbein GW, and Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension 36: 878-884, 2000.
108. Lai EY, Solis G, Luo Z, Carlstrom M, Sandberg K, Holland S, Wellstein A, Welch WJ, and Wilcox CS. p47(phox) is required for afferent arteriolar contractile responses to angiotensin II and perfusion pressure in mice. Hypertension 59: 415-420, 2012.
109. Landmesser U, Cai H, Dikalov S, McCann L, Hwang J, and Jo H. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40: 511-515, 2002.
110. Lassegue B and Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285: R277-R297, 2003.
111. Lassegue B and Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30: 653-661, 2010.
112. Lassegue B, San Martn A, and Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 110: 1364-1390, 2012.
113. Laude K, Cai H, Fink B, Hoch N, Weber DS, McCann L, Kojda G, Fukai T, Schmidt HH, Dikalov S, Ramasamy S, Gamez G, Griendling KK, and Harrison DG. Hemodynamic and biochemical adaptations to vascular smooth muscle overexpression of p22phox in mice. Am J Physiol Heart Circ Physiol 288: H7-H12, 2005.
114. Laurindo FR, Pescatore LA, and Fernandes Dde C. Protein disulfide isomerase in redox cell signaling and homeostasis. Free Radic Biol Med 52: 1954-1969, 2012.
115. Lavi S, Yang EH, Prasad A, Mathew V, Barsness GW, Rihal CS, Lerman LO, and Lerman A. The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. Hypertension 51: 127-133, 2008.
116. Lee DH, Gold R, and Linker RA. Mechanisms of oxidative damage in multiple sclerosis and neurodegenerative diseases: therapeutic modulation via fumaric acid esters. Int J Mol Sci 13: 11783-11803, 2012.
117. Lee J, Giordano S, and Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J 441: 523-540, 2012.
118. Leto TL, Morand S, Hurt D, and Ueyama T. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid Redox Signal 11: 260-267, 2009.
119. Lob HE, Schultz D, Marvar PJ, Davisson RL, and Harrison DG. Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension. Hypertension 61: 382-387, 2013.
120. Loffredo L, Carnevale R, Cangemi R, Angelico F, Augelletti T, Di Santo S, Calabrese CM, Della Volpe L, Pignatelli P, Perri L, Basili S, and Violi F. NOX2 up-regulation is associated with artery dysfunction in patients with peripheral artery disease. Int J Cardiol 165: 184-192, 2013.
121. Loffredo L, Carnevale R, Sanguigni V, Plebani A, Rossi P, Pignata C, De Mattia D, Finocchi A, Martire B, Pietrogrande MC, Martino S, Gambineri E, Giardino G, Soresina AR, Martino F, Pignatelli P, and Violi F. Does NADPH oxidase deficiency cause artery dilatation in humans? Antioxid Redox Signal 8: 1491-1496, 2013.
122. Lopes HF, Martin KL, Nashar K, Morrow JD, Goodfriend TL, and Egan BM. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension 41: 422-430, 2003.
123. Loukogeorgakis SP, van den Berg MJ, Sofat R, Nitsch D, Charakida M, Haiyee B, de Groot E, MacAllister RJ, Kuijpers TW, and Deanfield JE. Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation 121: 2310-2316, 2010.
124. Ma L, Gul R, Habibi J, Yang M, Pulakat L, Whaley-Connell A, Ferrario CM, and Sowers JR. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol 302: H2341-H2351, 2012.
125. Manea A, Manea SA, Florea IC, Luca CM, and Raicu M. Positive regulation of NADPH oxidase 5 by proinflammatoryrelated mechanisms in human aortic smooth muscle cells. Free Radic Biol Med 52: 1497-1507, 2012.
126. Manea A, Tanase LI, Raicu M, and Simionescu M. Jak/ STAT signaling pathway regulates nox1 and nox4-based NADPH oxidase in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 30: 105-112, 2010.
127. Manea A, Tanase LI, Raicu M, and Simionescu M. Transcriptional regulation of NADPH oxidase isoforms Nox1 and Nox4, by nuclear factor-kappaB in human aortic smooth muscle cells. Biochem Biophys Res Commun 396: 901-907, 2010.
128. Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J, Bosch J, Dagenais GR, and Yusuf S; HOPE Investigators. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int 65: 1375-1380, 2004.
129. Matsuno K, Yamada H, Iwata K, Jin D, Katsuyama M, Matsuki M, Takai S, Yamanishi K, Miyazaki M, Matsubara H, and Yabe-Nishimura C. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation 112: 2677-2685, 2005.
130. Mazzanti L, Raffaelli F, Vignini A, Nanetti L, Vitali P, Boscarato V, Giannubilo SR, and Tranquilli AL. Nitric oxide and peroxynitrite platelet levels in gestational hypertension and preeclampsia. Platelets 23: 26-35, 2012.
131. McCance DR, Holmes VA, Maresh MJ, Patterson CC, Walker JD, Pearson DW, and Young IS; Diabetes and Pre-eclampsia Intervention Trial (DAPIT) Study Group. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet 376: 259-266, 2010.
132. McQueen MJ, Lonn E, Gerstein HC, Bosch J, and Yusuf S. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest Suppl 240: 143-156, 2005.
133. Meng FG and Zhang ZY. Redox regulation of protein tyrosine phosphatase activity by hydroxyl radical. Biochim Biophys Acta 1834: 464-469, 2013.
134. Miller BA and Zhang W. TRP channels as mediators of oxidative stress. Adv Exp Med Biol 704: 531-544, 2011.
135. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, Li M, Raggio J, Wellstein A, Chen Y, Welch WJ, and Wilcox CS. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension 47: 238-244, 2006.
136. Montezano AC, Burger D, Ceravolo GS, Yusuf H, Montero M, and Touyz RM. Novel Nox homologues in the vasculature: focusing on Nox4 and Nox5. Clin Sci (Lond) 120: 131-141, 2011.
137. Montezano AC, Paravicini TM, Chignalia AZ, Yusuf H, Almasri M, He Y, He G, Callera GE, Krause K-H, Lambeth D, and Touyz RM. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/ calmodulin-dependent pathways in human endothelial cells. Circ Res 106: 1363-1373, 2010.
138. Moran JP, Cohen L, Greene JM, Xu G, Feldman EB, Hames CG, and Feldman DS. Plasma ascorbic acid concentrations relate inversely to blood pressure in human subjects. Am J Clin Nutr 57: 213-217, 1993.
139. Moreau KL, Gavin KM, Plum AE, and Seals DR. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. Hypertension 45: 1107-1112, 2005.
140. Moreno MU, Jose GS, Fortuno A, Beloqui O, Diez J, and Zalba G. The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens 24: 1299-1306, 2006.
141. Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25: 279-286, 2005.
142. Mullan BA, Young IS, Fee H, and McCance DR. Ascorbic acid reduces blood pressure and arterial stiffness in type 2 diabetes. Hypertension 40: 804-809, 2002.
143. Myint PK, Luben RN, Wareham NJ, and Khaw KT. Association between plasma vitamin C concentrations and blood pressure in the European prospective investigation into cancer-Norfolk population-based study. Hypertension 58: 372-379, 2011.
144. Nagasaka H, Takayanagi M, and Tsukahara H. Children?s toxicology from bench to bed-liver injury: oxidative stress and anti-oxidant systems in liver of patients with Wilson disease. J Toxicol Sci 34: SP229-SP236, 2009.
145. Nautiyal M, Katakam PV, Busija DW, Gallagher PE, Tallant EA, Chappell MC, and Diz DI. Differences in oxidative stress status and expression of MKP-1 in dorsal medulla of transgenic rats with altered brain renin-Angiotensin system. Am J Physiol Regul Integr Comp Physiol 303: R799-R806, 2012.
146. Newberry SJ. What is the evidence that vitamin C supplements lower blood pressure? Am J Clin Nutr 95: 997-998, 2012.
147. Nguyen Dinh Cat A, Briones AM, Callera GE, Yogi A, He Y, Montezano AC, and Touyz RM. Adipocyte-derived factors regulate vascular smooth muscle cells through mineralocorticoid and glucocorticoid receptors. Hypertension 58: 479-488, 2011.
148. Nguyen Dinh Cat A, Montezano AC, Burger D, and Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal 19: 1110-1120, 2013.
149. Nishino T, Okamoto K, Eger BT, Pai EF, and Nishino T. Mammalian xanthine oxidoreductase-mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 275: 3278-3289, 2008.
150. Nisimoto Y, Tsubouchi R, Diebold BA, Qiao S, Ogawa H, Ohara T, and Tamura M. Activation of NAD(P)H oxidase 1 in tumour colon epithelial cells. Biochem J 415: 57-65, 2008.
151. Niu XL, Madamanchi NR, Vendrov AE, Tchivilev I, Rojas M, Madamanchi C, Brandes RP, Krause KH, Humphries J, Smith A, Burnand KG, and Runge MS. Nox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. Circulation 121: 549-559, 2010.
152. Nuyt AM. Mechanisms underlying developmental programming of elevated blood pressure and vascular dysfunction: evidence from human studies and experimental animal models. Clin Sci (Lond) 114: 1-17, 2008.
153. Oliveira PJ, Goncalves L, Monteiro P, Providencia LA, and Moreno AJ. Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria? Curr Vasc Pharmacol 3: 147-158, 2005.
154. Pandey D and Fulton DJ. Molecular regulation of NADPH oxidase 5 via the MAPK pathway. Am J Physiol Heart Circ Physiol 300: H1336-H1344, 2011.
155. Pandey D, Gratton JP, Rafikov R, Black SM, and Fulton DJ. Calcium/calmodulin-dependent kinase II mediates the phosphorylation and activation of NADPH oxidase 5. Mol Pharmacol 80: 407-415, 2011.
156. Pandey D, Patel A, Patel V, Chen F, Qian J, Wang Y, Barman SA, Venema RC, Stepp DW, Rudic RD, and Fulton DJ. Expression and functional significance of NADPH oxidase 5 (Nox5) and its splice variants in human blood vessels. Am J Physiol Heart Circ Physiol 302: H1919-H1928, 2010.
157. Paravicini TM, Montezano AC, Yusuf H, and Touyz RM. Activation of vascular p38MAPK by mechanical stretch is independent of c-Src and NADPH oxidase: influence of hypertension and angiotensin II. J Am Soc Hypertens 6: 169-178, 2012.
158. Pescatore LA, Bonatto D, Forti FL, Sadok A, Kovacic H, and Laurindo FR. Protein disulfide isomerase is required for platelet-derived growth factor-induced vascular smooth muscle cell migration, Nox1 NADPH oxidase expression, and RhoGTPase activation. J Biol Chem 287: 29290-29300, 2010.
159. Petry A, Weitnauer M, and Gorlach A. Receptor activation of NADPH oxidases. Antioxid Redox Signal 13: 467-472, 2010.
160. Knock GA and Ward JP. Redox regulation of protein kinases as a modulator of vascular function. Antioxid Redox Signal 15: 1531-1547, 2011.
161. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, and Griendling KK. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NAD(P)H oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97: 1916-1923, 1996.
162. Rathore R, Zheng YM, Niu CF, Liu QH, Korde A, Ho YS, and Wang YX. Hypoxia activates NADPH oxidase to increase [ROS]i and [Ca2 + ]i through the mitochondrial ROSPKCepsilon signaling axis in pulmonary artery smooth muscle cells. Free Radic Biol Med 45: 1223-1231, 2008.
163. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, and Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31: 1368-1376, 2011.
164. Renke M, Tylicki L, Rutkowski P, Larczynski W, Neuwelt A, Aleksandrowicz E, qysiak-Szyd1owska W, Rutkowski B. The effect of N-Acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebo-controlled, randomized, cross-over study. Med Sci Monit 16: PI13-PI18, 2010.
165. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, and Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O2-And systolic blood pressure in mice. Circ Res 89: 408-414, 2001.
166. Robbins IM, Hemnes AR, Gibbs JS, Christman BW, Howard L, Meehan S, Cabrita I, Gonzalez R, Oyler T, Zhao L, Du RH, Mendes LA, and Wilkins MR. Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension. Exp Lung Res 37: 26-34, 2011.
167. Roberts JM, Myatt L, Spong CY, Thom EA, Hauth JC, Leveno KJ, Pearson GD, Wapner RJ, Varner MW, Thorp JM, Jr., Mercer BM, Peaceman AM, Ramin SM, Carpenter MW, Samuels P, Sciscione A, Harper M, Smith WJ, Saade G, Sorokin Y, Anderson GB; and Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Vitamins C and E to prevent complications of pregnancy-Associated hypertension. N Engl J Med 362: 1282-1291, 2010.
168. Rock CL, Jahnke MG, Gorenflo DW, Swartz RD, and Messana JM. Racial group differences in plasma concentrations of antioxidant vitamins and carotenoids in hemodialysis patients. Am J Clin Nutr 65: 844-850, 1997.
169. Romanowski A, Murray IR, and Huston MJ. Effects of hydrogen peroxide on normal and hypertensive rats. Pharm Acta Helv 35: 354-357, 1960.
170. Saraswathi R, Sankar D, Ali A, Uehara Y, Abe S, Sambandam G, and Rao MR. A pilot assessment of oxidative stress byproducts and antioxidant activities among Indian patients with various stages of hypertension. Clin Exp Hypertens 33: 437-443, 2011.
171. Schallreuter KU, Moore J, Wood JM, Beazley WD, Gaze DC, Tobin DJ, Marshall HS, Panske A, Panzig E, and Hibberts NA. In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-Activated pseudocatalase. J Invest Dermatol Symp Proc 4: 91-96, 1999.
172. Schiffer E, Liabeuf S, Lacroix C, Temmar M, Renard C, Monsarrat B, Choukroun G, Lemke HD, Vanholder R, Mischak H, and Massy ZA. Markers of vascular disease in plasma from patients with chronic kidney disease identified by proteomic analysis. J Hypertens 29: 783-790, 2011.
173. Schiffrin EL. Antioxidants in hypertension and cardiovascular disease. Mol Interv 10: 354-362, 2010.
174. Schiffrin EL. T lymphocytes: a role in hypertension? Curr Opin Nephrol Hypertens 19: 181-186, 2010.
175. Schreiber R, Ferreira-Sae MC, Ronchi JA, Pio-Magalhaes JA, Cipolli JA, Matos-Souza JR, Mill JG, Vercesi AE, Krieger JE, Franchini KG, Pereira AC, and Nadruz Junior W. The C242T polymorphism of the p22-phox gene (CYBA) is associated with higher left ventricular mass in Brazilian hypertensive patients. BMC Med Genet 12: 114-118, 2011.
176. Schro?der K, Wandzioch K, Helmcke I, and Brandes RP. Nox4 acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler Thromb Vasc Biol 29: 239-245, 2009.
177. Schulz E and Mu?nzel T. NOX5, a new radical player in human atherosclerosis? J AmColl Cardiol 52: 1810-1813, 2008.
178. Schupp N, Kolkhof P, Queisser N, Gartner S, Schmid U, Kretschmer A, Hartmann E, Oli RG, Schafer S, and Stopper H. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 25: 968-978, 2011.
179. Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CR, Burns KD, Touyz RM, and He?bert RL. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 299: F1348-F1358, 2010.
180. Sedeek M, Gutsol A, Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, Burns KD, Cooper ME, Jandeleit-Dahm K, Page P, Szyndralewiez C, Heitz F, Hebert RL, and Touyz RM. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond) 124: 191-202, 2013.
181. Sedeek M, Montezano AC, Hebert RL, Gray SP, Di Marco E, Jha JC, Cooper ME, Jandeleit-Dahm K, Schiffrin EL, Wilkinson-Berka JL, and Touyz RM. Oxidative stress, Nox isoforms and complications of diabetes-potential targets for novel therapies. J Cardiovasc Transl Res 5: 509-518, 2012.
182. Selmici L. Advanced oxidation protein products (AOPP): novel uremic toxins, or components of the non-enzymatic antioxidant system of the plasma proteome? Free Radic Res 45: 1115-1123, 2011.
183. Serg M, Kampus P, Kals J, Zagura M, Zilmer M, Zilmer K, Kullisaar T, and Eha J. Nebivolol and metoprolol: longterm effects on inflammation and oxidative stress in essential hypertension. Scand J Clin Lab Invest 72: 427-432, 2012.
184. Serrander L, Jaquet V, Bedard K, Plastre O, Hartley O, Arnaudeau S, Demaurex N, Schlegel W, and Krause KH. NOX5 is expressed at the plasma membrane and generates superoxide in response to protein kinase C activation. Biochimie 89: 1159-1167, 2007.
185. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, and Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91: 406-413, 2002.
186. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, and Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians? Health Study II randomized controlled trial. JAMA 300: 2123-2133, 2008.
187. Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, Manson JE, Glynn RJ, Buring JE, and Gaziano JM. Multivitamins in the prevention of cardiovascular disease in men: the Physicians? Health Study II randomized controlled trial. JAMA 308: 1751-1760, 2012.
188. Shaw JH and Lloyd PG. Post-transcriptional regulation of placenta growth factor mRNA by hydrogen peroxide. Microvasc Res 84: 155-160, 2012.
189. Sheehan AL, Carrell S, Johnson B, Stanic B, Banfi B, and Miller FJ, Jr. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis 216: 321-326, 2011.
190. Silva PS, Fontana V, Palei AC, Sertorio JT, Biagi C, and Tanus-Santos JE. Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers. Eur J Clin Pharmacol 67: 365-370, 2011.
191. Simic DV, Mimic-Oka J, Pljesa-ErcegovacM, Savic-Radojevic A, Opacic M, Matic D, Ivanovic B, and Simic T. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. J Hum Hypertens 20: 149-155, 2006.
192. Smith MPW, Banks RE, Wood SL, Lewington AJP and Selby PJ. Application of proteomic analysis to the study of renal diseases. Nat Rev Nephrol 5: 701-712, 2009.
193. Spychalowicz A, Wilk G, Sliwa T, Ludew D, and Guzik TJ. Novel therapeutic approaches in limiting oxidative stress and inflammation. Curr Pharm Biotechnol 13: 2456-2466, 2012.
194. Stanic B, Pandey D, Fulton DJ, and Miller FJ, Jr. Increased epidermal growth factor-like ligands are associated with elevated vascular nicotinamide adenine dinucleotide phosphate oxidase in a primate model of atherosclerosis. Arterioscler Thromb Vasc Biol 32: 2452-2460, 2012.
195. Stehr CB, Mellado R, Ocaranza MP, Carvajal CA, Mosso L, Becerra E, Solis M, Garca L, Lavandero S, Jalil J, and Fardella CE. Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients. J Hypertens 28: 2120-2126, 2010.
196. Streeter J, Thiel W, Brieger K, and Miller FJ, Jr. Opportunity Nox: the future of NADPH oxidases as therapeutic targets in cardiovascular disease. Cardiovasc Ther 31: 125-137, 2013.
197. Sundaram A, Siew Keah L, Sirajudeen KN, and Singh HJ. Upregulation of catalase and downregulation of glutathione peroxidase activity in the kidney precede the development of hypertension in pre-hypertensive SHR. Hypertens Res 36: 213-218, 2013.
198. Tabet F, Savoia C, Schiffrin EL, and Touyz RM. Differential calcium regulation by hydrogen peroxide and superoxide in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol 44: 200-208, 2004.
199. Tabet F, Schiffrin EL, Callera GE, He Y, Yao G, Ostman A, Kappert K, Tonks NK, and Touyz RM. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res 103: 149-154, 2008.
200. Takac I, Schro?der K, and Brandes RP. The Nox family of NADPH oxidases: friend or foe of the vascular system? Curr Hypertens Rep 14: 70-78, 2012.
201. Takac I, Schro?der K, Zhang L, Lardy B, Anilkumar N, Lambeth JD, Shah AM, Morel F, and Brandes RP. The Eloop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem 286: 13304-13313, 2011.
202. Takahashi N, Kozai D, Kobayashi R, Ebert M, and Mori Y. Roles of TRPM2 in oxidative stress. Cell Calcium 50: 279-287, 2011.
203. Terawaki H, Nakayama M, Miyazawa E, Murata Y, Nakayama K, Matsushima M, Miyazaki M, Sato H, Sato M, Sato T, Taguma Y, and Ito S. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: the Gonryo study. Clin Exp Nephrol 2012 Nov 29 [Epub ahead of print]; PMID: 23192770
204. Toba H, Nakagawa Y, Miki S, Shimizu T, Yoshimura A, Inoue R, Asayama J, Kobara M, and Nakata T. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-Arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res 28: 689-700, 2005.
205. Touyz RM and Montezano AC. Vascular Nox4: a multifarious NADPH oxidase. Circ Res 110: 1159-1161, 2012.
206. Touyz RM and Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens 19: 1245-1254, 2001.
207. Touyz RM and Schiffrin EL. Reactive oxygen species in vascular biology: implications in hypertension. Histochem Cell Biol 122: 339-352, 2004.
208. Touyz RM, Briones AM, Sedeek M, Burger D, and Montezano AC. NOX Isoforms and reactive oxygen species in vascular health. Mol Interv 11: 27-35, 2011.
209. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, and Schiffrin EL. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 90: 1205-1213, 2002.
210. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochard N, and Reudelhuber TL. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NAD(P)H oxidase. Hypertension 45: 530-537, 2005.
211. Touyz RM, Tabet F, and Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30: 860-866, 2003.
212. Touyz RM, Yao G, Quinn MT, Pagano PJ, and Schiffrin EL. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 25: 512-518, 2005.
213. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 14: 125-131, 2005.
214. Touyz RM. New insights into mechanisms of hypertension. Curr Opin Nephrol Hypertens 21: 119-121, 2012.
215. Trigueros-Motos L, Gonzalez JM, Rivera J, and Andres V. Hutchinson-Gilford progeria syndrome, cardiovasculardisease and oxidative stress. Front Biosci (Schol Ed) 3: 1285-1297, 2011.
216. Tyther R, Ahmeda A, Johns E, and Sheehan D. Protein carbonylation in kidney medulla of the spontaneously hypertensive rat. Proteomics Clin Appl 3: 338-346, 2009.
217. Ushio-Fukai M, Alexander RW, Akers M, and Griendling KK. p38 Mitogen-Activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. J Biol Chem 273: 15022-15029, 1998.
218. Valente AJ, Yoshida T, Murthy SN, Sakamuri SS, Katsuyama M, Clark RA, Delafontaine P, and Chandrasekar B. Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18. Am J Physiol Heart Circ Physiol 303: H282-H296, 2012.
219. Vaziri ND and Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2: 582-593, 2006.
220. Vaziri ND. Protective effect of Nrf2 and catalase in maternal diabetes-induced perinatal hypertension and kidney disease. Diabetes 61: 2400-2402, 2012.
221. Viel EC, Benkirane K, Javeshghani D, Touyz RM, and Schiffrin EL. Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 295: H281-H288, 2008.
222. Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, and Guzik TJ. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation 122: 2529-2537, 2010.
223. Violi F, Pignatelli P, Pignata C, Plebani A, Rossi P, Sanguigni V, Carnevale R, Soresina A, Finocchi A, Cirillo E, Catasca E, Angelico F, and Loffredo L. Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler Thromb Vasc Biol 33: 406-412, 2013.
224. Violi F, SanguigniV, Carnevale R, Plebani A, Rossi P, Finocchi A, Pignata C, De Mattia D, Martire B, Pietrogrande MC, Martino S, Gambineri E, Soresina AR, Pignatelli P,Martino F, Basili S, and Loffredo L. Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 120: 1616-1622, 2009.
225. Virdis A, Neves MF, Amiri F, Touyz RM, and Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens 22: 535-542, 2004.
226. WalkerAEand Kaplon RE, Lucking SM, Russell-Nowlan MJ, Eckel RH, Seals DR. Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults. Hypertension 60: 1517-1523, 2012.
227. White SJ, Hayes EM, Lehoux S, Jeremy JY, Horrevoets AJ, and Newby AC. Characterization of the differential response of endothelial cells exposed to normal and elevated laminar shear stress. J Cell Physiol 226: 2841-2848, 2011.
228. Wray DW, Nishiyama SK, Harris RA, Zhao J, McDaniel J, Fjeldstad AS, Witman MA, Ives SJ, Barrett-O?Keefe Z, and Richardson RS. Acute reversal of endothelial dysfunction in the elderly after antioxidant consumption. Hypertension 59: 818-824, 2012.
229. Wray DW, Uberoi A, Lawrenson L, Bailey DM, and Richardson RS. Oral antioxidants and cardiovascular health in the exercise-trained and untrained elderly: a radically different outcome. Clin Sci (Lond) 116: 433-441, 2009.
230. Wu KL, Chan SH, and Chan JY. Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. J Neuroinflammation 9: 212-216, 2012.
231. Wu RF, Ma Z, Liu Z, and Terada LS. Nox4-derived H2O2 mediates endoplasmic reticulum signaling through local Ras activation. Mol Cell Biol 30: 3553-3568, 2010.
232. Xu S, He Y, Vokurkova M, and Touyz RM. Endothelial cells negatively modulate reactive oxygen species generation in vascular smooth muscle cells: role of thioredoxin. Hypertension 54: 427-433, 2009.
233. Yogi A, Mercure C, Touyz J, Callera GE, Montezano AC, Aranha AB, Tostes RC, Reudelhuber T, and Touyz RM. Renal redox-sensitive signaling, but not blood pressure, is attenuated by Nox1 knockout in angiotensin II-dependent chronic hypertension. Hypertension 51: 500-506, 2008.
234. Young CN, Cao X, Guruju MR, Pierce JP, Morgan DA, Wang G, Iadecola C, Mark AL, and Davisson RL. ER stress in the brain subfornical organ mediates angiotensindependent hypertension. J Clin Invest 122: 3960-3964, 2012.
235. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, and Etayo JC. Vascular NADH/NAD(P)H oxidase is in-volved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 35: 1055-1061, 2000.
236. Zalba G, San Jose G, Moreno MU, Fortuno A, and Diez J. NADPH oxidase-mediated oxidative stress: genetic studies of the p22(phox) gene in hypertension. Antioxid Redox Signal 7: 1327-1336, 2005.
237. ZhangM, BrewerAC, Schro?derK, SantosCX,GrieveDJ,Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, and Shah AM. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A 107: 18121-18126, 2010.
238. Zimmerman MC, Sharma RV, and Davisson RL. Superoxide mediates angiotensin II-induced influx of extracellular calcium in neural cells. Hypertension 45: 717-723, 2005.
239. Zureik M, Galan P, Bertrais S, Mennen L, Czernichow S, Blacher J, Ducimetiere P, and Hercberg S. Effects of longterm daily low-dose supplementation with antioxidant vitamins and minerals on structure and function of large arteries. Arterioscler Thromb Vasc Biol 24: 1485-1491, 2004.